Tamoxifen adjuvant treatment duration in early breast cancer: Initial results of a randomized study comparing short-term treatment with long-term treatment

Journal of Clinical Oncology

Volumn 18, Issue 20, 2000, Pages 3507-3512

  Delozier, Thierry ^a   Spielmann, Marc ^a   Macé Lesec'h, Josette ^a   Janvier, Maud ^a   Hill, Catherine ^a   Asselain, Bernard ^a   Julien, Jean Pierre ^a   Weber, Béatrice ^a   Mauriac, Louis ^a   Petit, Jean Christophe ^a   Kerbrat, Pierre ^a   Malhaire, Jean Pierre ^a   Vennin, Philippe ^a   Leduc, B ^a   Namer, Moïse ^a  

^a FNCLCC   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; HORMONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG INDICATION; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0034667865     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.20.3507     Document Type: Article

References (13)

1. Tamoxifen for early breast cancer: An overview of the randomised trials
2. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer
3. Preliminary results from the Cancer Research Campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer
4. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
5. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer: The Scottish Cancer Trials Breast Group
6. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer
7. The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer
8. Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values
9. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer
10. Adjuvant tamoxifen in postmenopausal breast cancer: Preliminary results of a randomized trial
11. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer
12. Adjuvant tamoxifen in the management of operable breast cancer: The Scottish Trial-Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh